18F-mFBG Imaging for Myocardial Sympathetic Innervation

Launched by INNERVATE RADIOPHARMACEUTICALS LLC (FORMERLY: ILLUMINA RADIOPHARMACEUTICALS LLC) · May 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging agent called 18F-mFBG to see how well it can help doctors understand the sympathetic nerve function in patients with heart failure due to ischemic cardiomyopathy. The trial will include patients who have a weakened heart (with a left ventricular ejection fraction of 35% or less) and who have had an implantable cardioverter-defibrillator (ICD) for at least a year. Researchers want to find out how much 18F-mFBG is taken up in the heart compared to past treatments and whether there are differences in nerve function between patients who have had an ICD activation and those who haven't.

If you qualify for this study, you can expect to undergo imaging tests using 18F-mFBG, while also providing safety data to help researchers understand any potential side effects. Eligibility criteria include being stable with heart failure and having an ICD, while those with unstable heart conditions or without an ICD cannot participate. This research aims to improve how we monitor heart health and may help in the development of better treatments for heart failure in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Stable heart failure from ischemic cardiomyopathy, LVEF \< or = 35%, ICD implantation for at least 12 months
• Exclusion Criteria:
• • Unstable coronary artery disease, no ICD implantation